Moberg Pharma: Exciting year ahead - Redeye

Redeye sees a Q4 report that was uneventful as expected. The highlight for the year is the expected EU regulatory approval during 2023e. The long-term outlook for MOB-015 still looks bright. We see that Moberg Pharma is progressing as planned, and the EU approval during 2023 should be an important catalyst as we advance.

Länk till analysen i sin helhet: https://www.redeye.se/research/874593/moberg-pharma-exciting-year-ahead?utm_source=finwire&utm_medium=RSS